Elan CEO to pharma: lower cost of new groundbreaking treatments

Share this article:

Elan’s CEO Kelly Martin has issued a challenge to the pharmaceutical industry to overhaul its commercial model by offering groundbreaking new treatments at lower cost.

Martin told the Financial Times his company is to lead by example by doing so for its Alzheimer’s treatments.

“The psychology of the industry is that, if you are first, the price should be high,” he said. “The economic structure is unsustainable. The tension will grow and something has to give.”

Martin, head of the Ireland-based pharmaceuticals firm said there is a commercial advantage to building market share by offering lower-priced drugs over many years.

“We would consider using price as one of the parameters for strategically positioning this company for the long-term,” he said.

“You need low and flexible infrastructure costs but you can charge less if you continue to innovate,” Martin said.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.